NCT07342179Recruiting
CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)
CAR-T Immunomonitoring in Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma plasma cells. These modified T lymphocytes are called CAR T cells (chimeric antigen receptor T cells). The long-term persistence of these modified lymphocytes, or CAR-BCMA, is a recognized indicator of a good response to treatment. This research aims to study certain markers related to CAR-BCMA cell persistence. This research will be carried out in collaboration with the Laboratory of Ischemia Reperfusion, Metabolism and Sterile Inflammation in Transplantation (IRMETIST) INSERM unit U1313, located at the University of Poitiers. The proposed project will contribute to better patient care in the field of oncology, by identifying immunological cellular markers predictive of an effective response to anti-cancer treatments and/or immunotherapeutic targeting.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 13 Feb 2026
- Primary completion date
- 3 Oct 2032
- Lead sponsor
- Poitiers University Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07342179
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 13 Feb 2026 to the primary completion date, 3 Oct 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals receiving enhanced protection, namely minors, pregnant and/or breastfeeding women, individuals deprived of their liberty by a judicial or administrative decision, individuals residing in a healthcare or social care facility, adults under legal guardianship, and finally, patients in emergency situations
Other
- Patients with severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study.
- Simultaneous participation in another study with an ongoing exclusion period.
Who the study is looking for
- Patient aged 18 and over
- Patient with Multiple Myeloma according to international recommendations,
- Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.